10-K: Nutra Pharma Faces Going Concern Doubt Amid Losses, SEC Settlement

Nutra Pharma Corp. reported continued net losses and a significant working capital deficit for fiscal year 2024, raising substantial doubt about its ability to continue as a going concern, while also settling a major SEC lawsuit.

Summary

• Nutra Pharma is a biopharmaceutical company focused on autoimmune disorders, viral diseases, and pain, marketing homeopathic OTC pain relievers and developing drug candidates RPI-78M and RPI-MN.
• The company received US-FDA Orphan Designation for Pediatric Multiple Sclerosis in September 2015, which may reduce clinical trial costs and shorten approval timelines.
• In March 2022, Nutra Pharma brought all manufacturing in-house and began contract manufacturing for third parties, including related party Avini Health.
• Net loss decreased to $1,285,663 in 2024 from $1,393,356 in 2023.
• Net sales to unrelated customers increased by 19.82% to $246,309 in 2024, while net sales to related party Avini Health decreased by 62.54% to $145,841 as Avini began manufacturing its own products.
• Gross profit was $247,323 (63.07% margin) in 2024, down from $396,455 (66.64% margin) in 2023, primarily due to a $60,000 reserve for undelivered venom and slow-moving inventory.
• Selling, general, and administrative expenses decreased by 4.43% to $1,125,744 in 2024, partly due to reduced legal fees after the SEC settlement and a new arrangement with Avini.
• The company settled a major SEC lawsuit in March 2024, agreeing to pay a total of $680,235, comprising $520,940 in disgorgement, $59,295 in prejudgment interest, and a $100,000 civil penalty.
• As of December 31, 2024, the company had a working capital deficit of $14,892,355, a stockholders deficit of $14,807,914, and an accumulated deficit of $76,231,137.
• Net cash used in operating activities improved to $0.42 million in 2024 from $0.55 million in 2023.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly concerning filing due to persistent significant losses, explicit going concern doubts, and widespread delays in critical R&D activities, despite some operational improvements and legal settlements.

Positives

• Net loss decreased by 7.73% year-over-year, from $1,393,356 in 2023 to $1,285,663 in 2024.
• Net sales to unrelated customers increased by 19.82% to $246,309 in 2024.
• Selling, general, and administrative expenses decreased by 4.43% to $1,125,744 in 2024, partly due to reduced legal fees.
• Net cash used in operating activities improved by approximately $0.13 million year-over-year, from $0.55 million in 2023 to $0.42 million in 2024.
• The company successfully settled a major SEC lawsuit, resolving significant legal uncertainty, though with substantial financial penalties.
• Orphan Drug Designation by the US-FDA for Pediatric Multiple Sclerosis may greatly reduce clinical trial costs and shorten the timeline to potential drug approval.
• In-house manufacturing capabilities, expanded in March 2022, are expected to reduce product costs, increase margins, and allow faster product upgrades and new product launches.
• Gain on settlement of debts, accrued expense, and vendor payable increased significantly to $33,778 in 2024 from $8,150 in 2023.

Negatives

• The company incurred significant recurring net losses of $1,285,663 in 2024 and $1,393,356 in 2023.
• There is substantial doubt about the company's ability to continue as a going concern due to recurring losses, significant indebtedness in default, and working capital and stockholders deficits.
• The company had a working capital deficit of $14,892,355 and a stockholders deficit of $14,807,914 as of December 31, 2024.
• An accumulated deficit of $76,231,137 was reported as of December 31, 2024.
• Net sales to a related party (Avini Health) significantly decreased by 62.54% to $145,841 in 2024, as Avini began manufacturing its own products, impacting overall revenue.
• Gross profit margin declined from 66.64% in 2023 to 63.07% in 2024, primarily due to a $60,000 reserve for undelivered venom and slow-moving inventory.
• All planned clinical studies (MS Neuropathic Pain Phase IV, Chronic Back Pain Phase I, Chronic Back Pain Phase IV) are delayed due to lack of funding and insufficient revenues.
• None of the ethical drug candidates have received FDA approval, requiring a complex and costly regulatory process that takes several years, if ever.
• The company's common stock is on the OTC Market Groups Expert Market and is subject to penny stock rules, which adversely affects its liquidity and market price.
• Material weaknesses in internal control over financial reporting were identified, including a lack of qualified accounting personnel, inadequate segregation of duties, limited checks and balances, and a lack of independent directors and an independent audit committee.
• The SEC settlement imposed a total financial obligation of $680,235 on the company.
• Many convertible notes and other debts are in default and under negotiation for settlement.

Risks

• Material weaknesses in internal control over financial reporting could adversely affect financial condition, access to capital, and the market price of common stock.
• Substantial doubt exists about the company's ability to continue as a going concern without obtaining adequate new debt or equity financing and achieving sufficient sales levels.
• The company has a limited revenue-producing history with significant losses and expects losses to continue for the foreseeable future.
• Additional financing is required to sustain operations, and without it, the company will be unable to continue.
• A history of failed distributors has negatively affected revenues and may continue to do so if a successful distributor is not found.
• Inability to sell a sufficient volume of products will prevent the company from continuing in business.
• The company's growth strategy may be unachievable or may not result in profitability.
• Inability to manage growth effectively could prevent the company from becoming profitable.
• Failure to protect proprietary technology could harm the business.
• The company is subject to substantial FDA regulations pertaining to its products, which may increase costs or adversely affect operations.
• Inability to provide scientific proof for product claims may adversely affect sales.
• None of the ethical drug candidates have received FDA approval, and the process is complex and costly.
• Inability to secure sufficient cobra venom from available suppliers could negatively affect operating results.
• Nyloxin and Pet Pain-Away products may be unable to compete effectively against competitors in the pain relief market.
• Product liability claims exceeding policy limits could negatively affect operating results.
• Loss of any key personnel (CEO, Operations Manager, Chief Scientific Officer) could have a material adverse effect on operations and financial results.
• Inability to retain, hire, and integrate key management and operating personnel could hinder business expansion.
• Cybersecurity threats pose risks to the company's business, results of operations, or financial condition.
• The limited market for common stock (OTC Expert Market) and penny stock rules adversely affect its liquidity and market price.
• Sales of freely tradable shares could cause the market price of common stock to drop significantly.
• Future issuance of additional securities or exercise of options/warrants could result in substantial dilution to existing shareholders.
• Purchasers will suffer substantial dilution due to the company's negative net tangible book value.
• No dividends are expected for the foreseeable future.
• The stock price may continue to be volatile due to factors beyond the company's control.
• Securities class action litigation could result in substantial costs and divert management's time.
• Failure to successfully develop and commercialize products from research and development activities.
• Failure to compete effectively in the intensely competitive biotechnology area.
• Failure to successfully execute planned partnering and out-licensing of products or technologies.
• The economic downturn and related credit and financial market crisis may adversely affect the ability to obtain financing.
• Biotechnology industry-related litigation is substantial and may continue to rise.
• The decline in sales to Avini is expected to reduce future revenues and may require developing new customer relationships.
• Failure to comply with extensive legal/regulatory requirements affecting the healthcare industry will lead to increased costs and potential business losses.

Future Outlook

The company plans to re-engage in the regulatory approval process for Nyloxin in Canada in 2026 and aims to complete several human clinical studies for Nyloxin Extra Strength, contingent on adequate financing. It also intends to initiate Phase I/II clinical studies in Pediatric MS in 2026, leveraging its Orphan Designation. Mid-term strategy involves licensing AMN, MS, and HIV technologies within five years, also dependent on securing sufficient financing. Long-term goals focus on the use of its drugs in neurological, infectious, and autoimmune disorders, which will require establishing strategic partnerships or alliances.

Management Comments

• "Expanding our in-house manufacturing capabilities has put Nutra Pharma in a very good position as far as reduced product costs, higher margins, faster product upgrades and an increased ability to launch new and innovative products."
• "Our goal is that with Nyloxin, we can greatly reduce the instances of opiate abuse and overuse of NSAIDS in high risk groups like the US military."
• "The consensus of the comments and questions on the presentation supported the idea that despite past efforts, there remains an unmet need for nAChR directed defenses and that our demonstration of human safety in the clinic and pre-clinical proof of concept deserves aggressive follow up."

Industry Context

StockSavvy.ai notes that the global chronic pain intervention market reached $78.79 billion in 2024 and is projected to exceed $117 billion by 2029, indicating a substantial addressable market for Nutra Pharma's pain relievers. The U.S. multiple sclerosis drugs market is also expected to grow significantly from $7.81 billion in 2024 to $17.15 billion by 2034, driven by R&D and regulatory approvals, which aligns with Nutra Pharma's RPI-78M development efforts. However, the company faces intense competition from major pharmaceutical and biotechnology firms such as Amgen, Sanofi-Aventis, Biogen-Idec, and Roche, which possess vastly superior financial, technological, and operational resources. The high median annual price of brand-name MS disease-modifying therapies, close to $94,000, underscores the high-value potential of successful drug development in this therapeutic area.

Comparison to Industry Standards

• Nutra Pharma's RPI-78 (Cobratoxin) demonstrated pain-reducing effects that lasted four times as long as morphine without the negative side effects associated with opioid-based pain relievers in a study published in Toxicon, suggesting a potentially superior safety and duration profile compared to traditional opiates like Dolantin.
• RPI-78 was calculated to be 150,000 times more potent than aspirin, indicating a significantly higher efficacy potential compared to widely used over-the-counter pain relievers.
• The company's focus on non-narcotic, non-addictive pain relief products like Nyloxin offers a differentiated alternative in a market increasingly concerned with the risks of opioid and NSAID overuse, positioning it against conventional pharmaceutical offerings.
• The Orphan Drug Designation for Pediatric MS provides Nutra Pharma with a 7-year period of market exclusivity in the U.S. upon drug approval, a substantial advantage over standard drug development pathways that lack such regulatory incentives and protection.
• Financially, Nutra Pharma's significant accumulated deficits, working capital deficits, and explicit going concern doubts stand in stark contrast to the robust financial health and extensive R&D budgets of industry leaders like Amgen, Sanofi-Aventis, and Biogen-Idec.

Management Changes

Corporate Governance

Legal Proceedings

• **Marc Weller v. Nutra Pharma Corporation, Case No. CACE-24-018346**: Settled in January 2026. The company agreed to cancel and extinguish outstanding notes with an aggregate carrying value of approximately $175,000 in exchange for $20,000 in cash (payable in installments through April 2026) and the issuance of 60 million shares of common stock.
• **CSA 8411, LLC v. Nutra Pharma Corp., Case No. CACE 18-023150**: A lawsuit filed on October 12, 2018, to recover $100,000. The case was settled on May 19, 2025, for a total obligation of $125,000, with an initial payment of $35,000 and nine monthly payments of $10,000. A payment default could lead to a consent judgment of $400,000.
• **Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus**: A lawsuit filed on September 28, 2018, alleging fraud and violations of federal securities laws. The case was settled in March 2024. The company was permanently enjoined from certain violations and ordered to pay $520,940 in disgorgement, $59,295 in prejudgment interest, and a $100,000 civil penalty (totaling $680,235). Rik J. Deitsch received a three-year officer-and-director bar and penny-stock bar, along with monetary penalties. Sean Peter McManus received a two-year penny-stock bar and monetary penalties.

Related Party Transactions

• **Due to Officers**: At December 31, 2024, the balance due to Rik Deitsch (former CEO) and his controlled companies was $986,264, unsecured and accruing interest at 4%. During 2024, $206,982 was repaid, and $530,396 was advanced on this balance.
• **Reclassification of Convertible Notes**: In March 2024, $253,000 in convertible notes (issued 2021-2022) were reclassified to 'due to officer' upon Michael Flax's appointment as CEO. These notes are currently in default.
• **Debt owed to a Director**: At December 31, 2024, $189,961 in accrued interest was owed to a director from a $200,000 loan originated in 2010 (principal repaid by 2016). This loan is in default and personally guaranteed by Mr. Deitsch.
• **Avini Health (Related Party)**: The company acts as a product formulator and contract manufacturer for Avini Health, which is owned by the former CEO, Rik Deitsch. Sales to Avini Health significantly decreased from $389,316 in 2023 to $145,841 in 2024 as Avini began manufacturing its own products.
• **Rent-Free Arrangement with Avini**: In September 2023, the company relocated its operations to Avini Health's leased facility in Boca Raton, using the space rent-free and sharing resources, with Avini paying all lease and office-related expenses.
• **Equipment Sale to Avini**: In 2023, the company sold certain equipment to Avini for approximately $83,600 (carrying amount $43,900), resulting in a gain of approximately $39,700.
• **Avini Debt Forgiveness**: Avini Health agreed to forgive a total of $240,557 in debt, which the company accounted for as a capital contribution, increasing Additional Paid-In Capital.
• **Deferred Revenue and Accounts Receivable with Avini**: As of December 31, 2024, the company had deferred revenue of $234,757 and accounts receivable of $5,800 related to Avini.
• **Accrued Payroll Due to Officers**: Accrued payroll due to officers, including the former CEO, was $1,641,554 at December 31, 2024.
• All related party transactions were not conducted at arm's length and may not reflect terms agreed to with an unrelated third party.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing and future capital raises, potential for continued stock price volatility due to penny stock status and limited market, and no dividends are expected. The SEC settlement and persistent going concern doubts negatively impact shareholder value and confidence.
• **Employees**: The company employs 6 individuals, but its financial instability and reliance on officer loans pose risks to job security. New officers have been appointed, indicating some management restructuring.
• **Customers**: Potential for inconsistent product availability and distribution delays if the company struggles with cobra venom supply or fails to secure adequate sales and marketing channels.
• **Creditors**: Many debts are in default, indicating high credit risk. Settlements with some creditors involve cash payments and stock issuance, which may affect the recovery prospects for other outstanding obligations.
• **Management**: The new CEO and VP of Operations face substantial challenges in securing funding, improving sales, addressing material weaknesses in internal controls, and navigating complex legal and regulatory environments.

Next Steps

• Re-engage in the regulatory approval process for Nyloxin in Canada in 2026.
• Complete several human clinical studies aimed at comparing Nyloxin Extra Strength to prescription pain relievers, pending adequate financing.
• Reinitiate MS Neuropathic Pain Phase IV trial, pending adequate funding.
• Reinitiate Chronic Back Pain Phase I trial, pending adequate funding.
• Reinitiate Chronic Back Pain Phase IV trial, pending adequate funding.
• Prepare for a pre-IND meeting with the FDA to gain approval for a Phase I/II clinical study in Pediatric MS.
• Initiate Phase I/II clinical studies in Pediatric MS in 2026.
• Develop an orally administered RPI-78M, pending adequate funding.
• License AMN, MS, and HIV technologies within 5 years, contingent on adequate financing.
• Establish strategic partners or alliances for long-term goals in neurological, infectious, and autoimmune disorders.
• Continue identifying biotechnology intellectual property and companies for potential acquisition.
• Supplement accounting staff with additional experienced financial professionals when financially able.
• Redefine and realign responsibilities and define additional controls, reporting processes, and procedures to address accounting requirements.
• Engage independent directors and a qualified independent audit committee when financially able.
• Engage third-party consultants to assist in accounting for complex transactions and disclosures until appropriate personnel are hired.
• Seek a new Chief Financial Officer, pending funding.
• Make remaining installment payments for the Marc Weller settlement through April 2026.
• Make nine monthly payments of $10,000 for the CSA 8411 settlement, beginning June 19, 2025.

Key Dates

Recommendation

The company explicitly states "substantial doubt about our ability to continue as a going concern," underpinned by significant recurring net losses, a massive accumulated deficit, and severe working capital and stockholders deficits. All major R&D projects are delayed due to a lack of funding, and sales to a key related party customer have sharply declined. While a major SEC lawsuit has been settled, it incurred a significant financial penalty. The presence of material weaknesses in internal controls and a lack of independent directors further exacerbates governance risks. Given the profound financial instability, operational challenges, and governance issues, the stock presents an extremely high risk, and a seasoned investor would strongly recommend selling or avoiding this investment.

Keywords

Biopharmaceutical, Pain Relief, Autoimmune Disorders, Viral Diseases, Orphan Drug, Multiple Sclerosis, HIV, Homeopathic Drugs, SEC Settlement, Going Concern, RPI-78M, RPI-MN, Nyloxin, Pet Pain-Away, Contract Manufacturing, OTC Market, Drug Development, Corporate Governance, Financial Reporting, Cobra Venom